Comparison of preferences for health outcomes in schizophrenia among stakeholder groups

Journal of Psychiatric Research

Volumn 34, Issue 3, 2000, Pages 201-210

  Lee, Tina T ^e   Ziegler, Jennifer K ^a   Sommi, Roger ^b   Sugar, Catherine ^e   Mahmoud, Ramy ^e   Lenert, Leslie A ^c,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e NONE

Author keywords

Computers; Cost effectiveness analysis; Health states; Multimedia; Outcomes; Preferences; Quality of life; Schizophrenia; Utilities

Indexed keywords

ADULT; AGED; ARTICLE; AUDIOVISUAL EQUIPMENT; CLINICAL ARTICLE; COMPUTER; COMPUTER PROGRAM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH STATUS; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; SCHIZOPHRENIA;

ADULT; AGED; ATTITUDE TO HEALTH; COST-BENEFIT ANALYSIS; FEASIBILITY STUDIES; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PARKINSONIAN DISORDERS; PILOT PROJECTS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES;

EID: 0034193840     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(00)00009-1     Document Type: Article

References (29)

1. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Archives of General Psychiatry. 39:(7):1982;789-794.
2. Beasley C.M. Jr, Tollefson G.D., Tran P.V. Efficacy of olanzapine: An overview of pivotal clinical trials. Journal of Clinical Psychiatry. 58:(Suppl. 10):1997;7-12.
3. Bennett K.J., Torrance G.W. Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques. Spiker B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. 1996;Lippincott-Raven, Philadelphia, PA.
4. Chouinard G., Albright P. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology. 17:(4):1997;298-307.
5. Davis J., Janicak P. Risperidone: A new, novel (and better?) antipsychotic. Psychiatric Annals. 26:(2):1996;78-87.
6. Detsky A., Naglie I. A clinician's guide to cost-effectiveness analysis. Annals of Internal Medicine. 113:1990;147-154.
7. Finn S., Bailey M., Schultz R., Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine. 20:1990;843-848.
8. Fuchs V.R., Garber A.M. The new technology assessment [published erratum appears in New England Journal of Medicine 1991, Jan 10; 324(10) 136] [see comments]. New England Journal of Medicine. 323:(10):1990;673-677.
9. Gold M.R., Patrick D.L., Torrance G.W., et al. Identifying and valuing outcomes. Gold M.R., Russel L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York.
10. Hedlund J.L., Vieweg B.W. The brief psychiatric rating scale: A comprehensive review. Journal of Operational Psychiatry. 11:1980;49-65.
11. Kaufman L., Rousseeuw P.J. Finding groups in data: an introduction to cluster analysis. 1990;Wiley, New York.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 13:(2):1987;261-276.
13. Lenert L.A., Morss S., Goldstein M.K., Garber A.M. Measurement of the validity of utility elicitations performed by computer interview. Medical Care. 35:(9):1997;915-920.
14. Lenert L., Soetikno R. Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis. The Journal of the American Medical Informatics Association. 4:(1):1997;49-56.
15. Lenert L.A., Treadwell J. Effect failure to maintain procedural invariance on utility elicitations. Medical Decision Making. 19:(4):1999;473-481.
16. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. 151:(6):1994;825-835.
17. McNeil B.J., Pauker S.G., Sox H. Jr, Tversky A. On the elicitation of preferences for alternative therapies. New England Journal of Medicine. 306:(21):1982;1259-1262.
18. Morss S.E., Lenert L.A., Faustman W.O. The side effects of antipsychotic drugs and patients' quality of life: patient education and preference assessment with computers and multimedia. Proceedings of the Annual Symposium on Computer Applications in Medical Care. 1993;17-21.
19. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports. 10:1962;799-812.
20. Revicki D., Shakespear A., Kind P. Preference for schizophrenia related health states: a comparison of patients, caregivers, and psychiatrists. International Journal of Psychopharmacology. 11:(2):1996;101-108.
21. Rutten-van Molken M.P., Bakker C.H., van Doorslaer E.K., van der Linden S. Methodological issues of patient utility measurement. Experience from two clinical trials. Medical Care. 33:(9):1995;922-937.
22. Sackett D.L., Torrance G.W. The utility of different health states as perceived by the general public. Journal of Chronic Diseases. 31:(11):1978;697-704.
23. Sanger T. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry. 154:1997;466-474.
24. Soetikneo R.M., Mrad R., Pao V., Lenert L.A. Quality of life research on the Internet. Feasibility and potential biases in ulcerative colitis patients. Journal of the American Medical Informatics Association. 4:(6):1997;426-435.
25. Sugar C., Sturm R., Lee T.T., et al. Utility weights for the SF-12 inventory for depressed patients: An empirical approach to identify relevant health states. Health Services Research. 33:(4 Pt 1):1998;911-928.
26. Torrance G.W. Measurement of health state utilities for economic appraisal. Journal of Health Economics. 5:1986;1-30.
27. von Neumann J., Morgenstern O. Theories of games and economic behavior. 1947;Princeton University Press, Princeton, NJ.
28. Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine. 296:(13):1977;716-721.
29. Woerner M.G., Mannuzza S., Kane J.M. Anchoring the BPRS: An aid to improved reliability. Psychopharmacology Bulletin. 24:(1):1988;112-117.